Key result
In healthy individuals, insulin infusion did not alter flow-mediated dilatation, but co-infusion with clonidine increased vascular responses to glyceryltrinitrate by 45%.
Why the study?
Does insulin infusion affect endothelium-independent and endothelium-dependent vasodilation in healthy individuals, and is this mediated by sympathetic activation?
Does insulin infusion affect endothelium-independent and endothelium-dependent vasodilation in healthy individuals, and is this mediated by sympathetic activation?
Answers are grounded in this paper and cite their sources.
This editorial highlights evidence that in healthy individuals, insulin-induced decreases in endothelium-independent vascular relaxations may be mediated by sympathetic activation.
Several items of information and data have been collected in the past few years on the complex interrelationships between insulin, endothelial function and the sympathetic nervous system [1,2]. Four pieces of background information are essential for understanding and correctly interpreting the value and potential limitations of the new intriguing findings provided in the study by Morgantini et al. [3] published in the present issue of the Journal of Hypertension. The first piece of background information is that the well recognized action of insulin is to promote glucose uptake into the skeletal muscle and that this effect is accompanied by an increase in skeletal muscle blood flow (Fig. 1, left panel) [1,2]. The second set of available data refers to the evidence that insulin potentiates nitric oxide release from the endothelial and smooth muscle cells of the vasculature ‘in vitro’ (Fig. 1, middle panel) [4,5]. The release of nitric oxide potentiates acetylcholine-induced vasodilation in normotensive individuals and in patients with essential hypertension ‘in vivo’ and thus enhances blood flow in the skeletal muscle (Fig. 1, middle panel) [6,7]. A third set of information refers to the finding that insulin at doses sufficient to cause hypoglycemia triggers an increase in forearm blood flow [8,9]. Interestingly, in individuals who displayed blood glucose levels maintained at constant levels via the euglycemic clamp approach the same doses of insulin also caused marked increases in forearm blood flow, a finding that stresses the importance of the direct effect that insulin has in determining vasodilatation [2,8]. Finally, it has been reported that insulin infusions at doses capable of triggering hypoglycemia (0.1, 0.5 and 1.0 mU/kg per min) increase circulating plasma levels of norepinephrine and epinephrine concentration as well [10]. Furthermore, pretreatment of 21 individuals with intra-arterial propranolol attenuated or completely inhibited the changes in forearm blood flow induced by insulin [11]. Since alpha-blockade was unable to abolish the insulin-related increase in forearm blood flow, the conclusion has been drawn that insulin at physiological levels causes forearm vasodilation primarily via an adrenergic mechanism mainly mediated by beta-receptors [11]. The overall picture is made even more complex by the finding that a profound dissociation exists between the peripheral vascular effects and the central nervous system action of insulin, given the evidence that this hormone at doses unable to affect arterial blood pressure values promotes a marked stimulation of the central sympathetic neural outflow (directly measured in humans in the peroneal or brachial nerve via the microneurographic recording of the efferent postganglionic sympathetic nerve traffic) coupled with the already mentioned skeletal muscle vasodilation [12,13].FIGURE 1: Scheme illustrating the classic and new hypothesis on the relationships between insulin, endothelial function and the sympathetic nervous system (SNS).The study by Morgantini et al. [3] brings out some of the very basic questions of the effects of insulin on endothelium-independent and endothelium-dependent vasodilation, the impact of the presence of hypoglycemia or hyperglycemia with insulin treatment and the regulation of blood pressure as well as vasomotor tone in patients with diabetes mellitus. Previous reports have shown that in healthy individuals a prolonged (2–4 h) low-dose insulin infusion at normal blood glucose values causes a severe impairment in flow-mediated dilatation of conductance arteries [14,15]. The reasons for this insulin effect in healthy individuals remain largely undefined. It is worthy to note, however, that the conclusion drawn from these studies warrants that the effect of insulin on flow-mediated dilatation should be analyzed taking into account two key parameters, that is the changes in plasma glucose levels and the infusion doses and duration of insulin. With this background in mind, Morgantini et al. aimed at two major goals in their study [3]. First, to confirm that insulin has such a profound negative effect on flow-mediated dilatation and second to verify whether and to what extent insulin still exerts this negative effect when its central excitatory effect on the sympathetic nervous system is prevented. The authors used 0.25 mU/kg per min insulin infusion on individuals (n = 5) whose plasma glucose levels were clamped by variable infusion of 20% glucose solution. In these individuals, insulin infusion alone did not alter flow-mediated dilatation contrary to what had been reported by Creager et al. [11]. The vasodilatatory responses to sublingual glyceryl trinitrate were decreased by approximately 25% as compared with control, but the data presented did not achieve statistical significance. Based on statistical analysis, it can be argued that sublingual glyceryl trinitrate response was not affected and thus endothelium-independent arterial dilations were not altered. Alternatively, it can be argued that with insulin infusion, the release of endogenous nitric oxide should have caused an increase in vascular diameter, and infusion of glyceryl trinitrate on top of this would have not increased the arterial diameter further. Thus, the calculated glyceryl trinitrate-induced increase in arterial diameter will not be evident. Confronted with this argument, the authors have specifically mentioned that the basal artery diameter was not altered with insulin infusion alone, something that is against widely reported findings. Nitric oxide levels in these individuals were not measured, but plasma norepinephrine increased and epinephrine levels did not change after insulin infusion, two findings that are in sharp contrast with the data provided by Creager et al. in their study [11]. Infusion of clonidine (a central alpha2-receptor blocker used at the dose of 0.0052 μg/min per kg) with insulin did not alter the flow-mediated vasodilation, but increased vascular responses to glyceryltrinitrate by 45%. Thus, the conclusion was drawn that in healthy individuals, the insulin-induced decrease in endothelium-independent vascular relaxations was mediated by sympathetic neural factors and, more specifically, by sympathetic activation (Fig. 1, right panel). It was also inferred that insulin infusion (at doses amounting on average to 0.25 mU/kg per min) did not affect endothelium-independent vascular dilatation. In discussing the study results, some limitations of the model as well as of the methodologies used by Morgantini et al. [3] should be underlined. First, one of the crucial results of the study relates to the role of sympathetic function, which has been assessed by the authors through the assay of the circulating plasma levels of the adrenergic neurotransmitter norepinephrine and epinephrine. Although the method used was the simplest one to achieve information on sympathetic function, it should be considered that in several circumstances and conditions, circulating plasma levels of the adrenergic neurotransmitters cannot be regarded as faithful markers of sympathetic drive [16]. This is particularly the case when there is the need, such as in the present study, to define whether and to what extent an acute experimental intervention, such as insulin infusion, which also profoundly modifies peripheral blood flow (and thus tissue catecholamine clearance), is accompanied by sympathetic changes. Indeed, the use of the already mentioned sympathetic nerve traffic recording or regional norepinephrine spillover technique [16], although complex and difficult to be performed, would appear to be more appropriate and capable of providing more reliable data on adrenergic influences to peripheral blood vessels under insulin infusion. A second caveat comes from the fact that for each subgroup of experiments included in the study, the number of individuals appears limited. There were no more than five individuals per group and thus the conclusions were often drawn from borderline differences between groups or without sufficient statistical power to detect significant differences. The study, however, has its undoubted merits and it may represent the background for future studies. This should be particularly the case for the investigations aimed at clarifying whether the insulin-related vasoconstriction and endothelial impairment is detectable in clinical conditions characterized by a marked adrenergic overdrive and insulin resistance such as obesity, metabolic syndrome and diabetes mellitus as well [16]. It will be worthy to investigate whether and to what extent pharmacological or nonpharmacological correction of the hyperadrenergic state may improve or even normalize the endothelial-dependent vascular responses to insulin. ACKNOWLEDGEMENTS Conflicts of interest There are no conflicts of interest.
No takes yet. Share an insight, caveat, or question.
Aggarwal et al. (2012) conducted an editorial in Healthy individuals (n=5). Insulin infusion vs. Control was evaluated on Flow-mediated dilatation and vasodilatatory responses to sublingual glyceryl trinitrate. In healthy individuals, insulin infusion did not alter flow-mediated dilatation, but co-infusion with clonidine increased vascular responses to glyceryltrinitrate by 45%.
Synapse has enriched 10 related papers. Consider them for comparative context: